Group 1 - The core inquiry from investors is about the annual production capacity of 2,5-dimethylfuran produced by the subsidiary Luhua Senxuan and whether there are plans for production expansion [2] - Luhua Senxuan primarily uses 2,5-dimethylfuran for the synthesis of urea-formaldehyde resin, with a portion utilized in the electrolyte for lithium iron phosphate batteries, but it is currently not used in solid-state batteries [2]

Market Overview - The Chinese medicine sector rose by 0.75% on September 1, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Chinese Medicine Sector - Zhendong Pharmaceutical (300158) closed at 9.21, up 6.11% with a trading volume of 1.2136 million shares and a turnover of 1.101 billion yuan [1] - Qidi Pharmaceutical (000590) closed at 12.33, up 4.14% with a trading volume of 140,800 shares and a turnover of 174 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.12, up 3.92% with a trading volume of 5.5195 million shares and a turnover of 1.165 billion yuan [1] Top Losers in Chinese Medicine Sector - Tianmu Pharmaceutical (600671) closed at 19.44, down 1.87% with a trading volume of 86,000 shares and a turnover of 170 million yuan [2] - Jilin Aodong (000623) closed at 20.13, down 1.66% with a trading volume of 284,000 shares and a turnover of 573 million yuan [2] - *ST Changyao (300391) closed at 4.19, down 1.64% with a trading volume of 86,000 shares and a turnover of 36.1 million yuan [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 29.7085 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2][3] - Notable net inflows from retail investors were observed in Yunnan Baiyao (000538) with 436.788 million yuan and in Zhongsheng Pharmaceutical (002317) with 82.0845 million yuan [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 188 million yuan from institutional investors, but a net outflow of 144 million yuan from speculative funds [3] - Zhongsheng Pharmaceutical (002317) saw a net inflow of 54.7945 million yuan from institutional investors, while retail investors experienced a net outflow of 82.0845 million yuan [3] - Dong'e Ejiao (000423) had a net inflow of 53.6307 million yuan from institutional investors, with a net outflow of 40.1030 million yuan from speculative funds [3]

Core Viewpoint - The company demonstrates resilience and growth potential in a complex industry environment, with steady revenue growth, significant cash flow improvement, and enhanced competitiveness of core products, alongside advancing internationalization and R&D innovation [1]. Financial Performance - For the first half of 2025, the company achieved revenue of 731 million yuan, a year-on-year increase of 1.54%; net profit attributable to shareholders was 131 million yuan, with a net profit of 127 million yuan after excluding non-recurring gains and losses, indicating solid profitability in core operations [2]. - The net cash flow from operating activities surged by 31.87% to 128 million yuan, reflecting improved operational quality and enhanced capital management efficiency [2]. Core Product Strength - Sales revenue from traditional Chinese medicine preparations grew by 12.45% year-on-year to 287 million yuan, serving as a key support for performance [3]. - Key products such as "Wang's Baochi Pill," "Jide Sheng Snake Medicine Tablets," and "Zheng Chai Hu Drink Granules" continue to gain clinical and market recognition due to their unique efficacy and strong brand heritage [3]. - "Wang's Baochi Pill" was included in the "International Clinical Practice Guidelines for Functional Dyspepsia in Traditional Chinese Medicine (2025 Edition)," enhancing its international influence [3]. International Expansion - The company actively expanded its overseas market, achieving self-operated export sales of 11.3 million USD, a year-on-year increase of 16% [4]. - Several raw material drug varieties have received FDA and CEP certifications, gaining international quality recognition [4]. R&D and Capacity Development - The company places high importance on R&D investment, collaborating with universities on various pharmacological and clinical research projects [5]. - The approval of new indications for "Diphenhydramine Hydrochloride Tablets" by the National Medical Products Administration further enriches the product line [5]. - Projects for traditional Chinese medicine preparation production bases, GMP certification upgrades, and energy-saving renovations are progressing steadily, laying the foundation for future capacity release and quality upgrades [5]. Cost Reduction and Efficiency Improvement - Through process optimization, intelligent equipment upgrades, and procurement cost control, the company achieved cost reductions exceeding 5 million yuan in the first half of the year [6]. - A successful stock incentive plan was implemented in May, granting 15.494 million restricted shares to 105 core employees, effectively motivating the team for long-term development [6]. Social Responsibility - The company continues to promote the construction of GAP bases for Chinese medicinal materials in Gansu Longxi, adopting a "leading enterprise + base + cooperative" model to boost local farmers' income [7]. - During the reporting period, the company procured local medicinal materials worth 30.946 million yuan, creating over 70 jobs, showcasing the responsibility and commitment of state-owned enterprises [7].

Core Points - The company has established an external guarantee system to regulate external guarantee behavior and control associated risks, aiming to protect investors' rights [1][2] - All directors and senior management are required to carefully manage and strictly control the debt risks arising from external guarantees [1] - External guarantees refer to the company providing guarantees for debts incurred by third parties, including subsidiaries, through various forms such as guarantees, mortgages, and pledges [1] Summary by Sections External Guarantee Principles - The external guarantee system outlines basic principles that must comply with laws, regulations, and the company's articles of association, including requiring counter-guarantees and careful assessment of the counterparty's ability [1] - No individual or unit is allowed to force the company to provide guarantees for others, and all external guarantees must be managed centrally [1] Approval Procedures - The company can provide guarantees for entities with independent legal status and strong debt repayment capabilities, requiring counter-guarantees for all but subsidiaries [1] - A thorough investigation of the credit status of the guaranteed party is mandatory to ensure the authenticity of the information and prevent fraud [1] - Different approval authorities are required for various situations, such as when the total amount of external guarantees exceeds 50% of the latest audited net assets, which must be approved by the shareholders' meeting [1] Contractual and Risk Management - Written guarantee contracts must be established, reviewed by the financial officer and legal department, and must clearly define all terms [2] - The finance department is responsible for safeguarding guarantee contracts and monitoring subsequent matters, ensuring that obligations are fulfilled upon debt maturity [2] - Any significant changes in the guaranteed party's situation require the company to take appropriate measures, and any violations by directors or related personnel resulting in losses must be legally accountable [2]

Group 1 - The company Jinghua Pharmaceutical (SZ 002349) announced on August 30 that its sixth board meeting was held on August 28, 2025, to review the proposal for the reappointment of the accounting firm [1] - For the first half of 2025, the company's revenue composition was entirely from the pharmaceutical industry, with a 100.0% share [1]

格隆汇8月29日丨精华制药(002349.SZ)公布2025年半年度报告，上半年公司实现营业收入7.31亿元，同 比增长1.54%；归属于上市公司股东的净利润1.31亿元，同比下降3.54%；归属于上市公司股东的扣除非 经常性损益的净利润1.27亿元，同比下降1.14%；基本每股收益0.1605元。 ...

证券代码：002349 证券简称：精华制药 公告编号：2025-030 精华制药集团股份有限公司 第六届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 精华制药集团股份有限公司（以下简称"公司"）第六届监事会第七次会议通 知于2025年8月11日以传真、专人送达、邮件等形式发出，会议于2025年8月28 日（星期四）以通讯和现场相结合的方式在公司会议室召开。会议应出席监事3 名，出席监事3名，会议的召开符合《中华人民共和国公司法》及《公司章程》 的有关规定，会议的召集、召开合法有效。会议由监事会主席秦建先生主持。 本次会议审议通过了以下议案： 1、审议通过了《2025年半年度报告全文及摘要》。 经过对公司2025年半年度报告进行全面的审核后，监事会认为董事会编制和 审核公司2025年半年度报告的程序符合法律、行政法规和中国证监会的相关规定， 报告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误 导性陈述或者重大遗漏。 表决结果：3票赞成；0票弃权；0票反对。 2、审议通过了《关于修改公司章程的议案》，并同意将该议案提 ...

证券代码：002349 证券简称：精华制药 公告编号：2025-029 精华制药集团股份有限公司 第六届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 精华制药集团股份有限公司（以下简称"公司"）第六届董事会第八次会议通 知于2025年8月11日以传真、专人送达、邮件等形式发出，会议于2025年8月28日 （星期四）在公司会议室以现场加通讯方式召开。会议应出席董事7名，实际出席 董事7名，公司监事及高级管理人员列席了会议，会议的召开符合《中华人民共和 国公司法》及《公司章程》的有关规定，会议的召集、召开合法有效。会议由董 事长尹红宇先生主持。 本次会议审议了以下议案： 1、审议通过了《2025年半年度报告全文及摘要》 《 2025 年 半 年 度 报 告 全 文 》 具 体 内 容 详 见 同 日 巨 潮 资 讯 网 （www.cninfo.com.cn），《2025 年半年度报告摘要》具体内容详见同日《中 国证券报》及巨潮资讯网（www.cninfo.com.cn）。 表决结果：7票赞成；0票弃权；0票反对。 2、审议通过了《关于修 ...

精华制药集团股份有限公司 章 程 二〇二五年八月 1 | 第一节 | 股份发行 | 6 | | --- | --- | --- | | 第二节 | 股份增减和回购 | 7 | | 第三节 | 股份转让 | 8 | | 第一节 | 股东的一般规定 | 9 | | 第二节 | 控股股东和实际控制人 12 | | | 第三节 | 股东会的一般规定 13 | | | 第四节 | 股东会的召集 | 15 | | 第五节 | 股东会的提案与通知 16 | | | 第六节 | 股东会的召开 | 17 | | 第七节 | 股东会的表决和决议 20 | | | 第一节 | 董事的一般规定 26 | | | 第二节 | 董事会 | 29 | | 第三节 | 独立董事 | 34 | | 第四节 | 董事会专门委员会 37 | | | 第一节 | 财务会计制度 | 41 | | 第二节 | 内部审计 | 44 | | 第三节 | 会计师事务所的聘任 45 | | | 第一节 | 通知 | 46 | | 第二节 | 公告 | 46 | | 第一节 | 合并、分立、增资和减资 47 | | | 第二节 | 解散和清算 | 48 | 第一 ...

精华制药集团股份有限公司 对外担保制度 第一章 总则 第一条 为了规范精华制药集团股份有限公司（下称"公司"）的对外担保 行为，有效控制公司对外担保风险，保护投资者合法权益，根据《中华人民共和 国公司法》、《中华人民共和国民法典》、《上市公司监管指引第 8 号——上市公司 资金往来、对外担保的监管要求》、和《深圳证券交易所上市公司自律监管指引》 等法律、法规、规范性文件以及《公司章程》的规定，特制订本管理制度。 第二条 公司全体董事及高级管理人员应当审慎对待和严格控制对外担保 产生的债务风险。 第三条 本制度所称"对外担保"，是指公司以第三人的身份为债务人（包 括公司的控股子公司）对于债务人所负的债务提供担保，当债务人不履行债务时， 由公司按照约定履行债务或者承担责任的行为。担保形式包括保证、抵押及质押。 本制度所称"公司及其控股子公司的对外担保总额"，是指包括公司对控股 子公司担保在内的公司对外担保总额与公司控股子公司对外担保总额之和。 公司下属子公司对外担保，公司派出董事应参照本管理制度的规定认真监督 管理，执行。 第四条 本制度所称控股子公司，是指公司持有其50%以上的股份,或者能够 决定其董事会半数以 ...